Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

Published:2019-11-15 Issue:6 Volume:61 Page:857-865
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Violet John,Sandhu Shahneen,Iravani Amir,Ferdinandus Justin,Thang Sue-Ping,Kong Grace,Kumar Aravind Ravi,Akhurst Tim,Pattison David,Beaulieu Alexis,Mooi Jennifer,Tran Ben,Guo Christina,Kalff Victor,Murphy Declan G,Jackson Price,Eu Peter,Scalzo Mark,Williams Scott,Hicks Rodney J.,Hofman Michael S.

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference33 articles.

1. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen;Smith-Jones;Cancer Res.,2000

2. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

3. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

4. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol;Hofman;BJU Int.,2018

5. Perera M Papa N Roberts M . Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions—a systematic review and meta-analysis. Eur Urol. February 14, 2019 [Epub ahead of print].

Cited by 210 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-03

2. Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial;European Urology;2024-09

3. Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer;EJNMMI Radiopharmacy and Chemistry;2024-08-24

4. Impact of Posttreatment SPECT/CT on Patient Management During¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy;Journal of Nuclear Medicine;2024-08-08

5. Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer;Nature Reviews Urology;2024-08-07